video overview

IIr Associates, Inc.
Publisher of The Virginia Engineer

Print-Publishing Services
Web Site Design-Coding-Hosting
Business Consulting

Phone: (804) 779-3527

Firm Announces Expansion of Consumer Healthcare R&D Center
November 8, 2019

GlaxoSmithKline plc (LSE/NYSE: GSK), a leading global healthcare company, has announced the company will invest $16.7 million to expand its consumer healthcare research and development center in the City of Richmond. GSK chose Virginia as one of three R&D laboratory hubs for their global Consumer Healthcare business.

GSK is a science-led, global healthcare company with a special purpose: to help people do more, feel better, and live longer. With three global businesses that research, develop, and manufacture innovative pharmaceutical medicines, vaccines, and consumer healthcare products, their goal is to be one of the world’s most innovative, best performing, and trusted healthcare companies.

In August of this year, GSK announced the completion of its transaction with Pfizer to combine consumer healthcare businesses into a world-leading consumer healthcare joint venture, which will be the largest over-the-counter healthcare company in the world. The joint venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren, and Panadol and Pfizer’s Advil, Centrum, and Caltrate. The existing R&D facility in the City of Richmond, formerly the Global R&D headquarters for Pfizer Consumer Healthcare, will be operated by the new consumer healthcare joint venture.

“The Commonwealth of Virginia and the City of Richmond provide an environment for GSK Consumer Healthcare to build leading R&D capabilities, including access to world-class talent and universities, while also offering an attractive cost of living and favorable business operating costs,” said Dr. Peter John Ramsey, PhD, Vice President and Head, GSK Consumer Healthcare R&D, The Americas.

“We are extremely proud that GSK will make a major investment in the City of Richmond and continue to grow its footprint in Virginia,” said Governor Ralph S. Northam in response to the announcement. “The greater Richmond region has emerged as a hub for leading biosciences companies, offering world-class education institutions, research assets, and a pipeline of skilled talent, and GSK’s consumer healthcare joint venture and expansion will further its position as a powerhouse in this industry. We thank GSK for its commitment to our Commonwealth, and stand ready to support the company’s success.”

The Virginia Economic Development Partnership (VEDP) worked with the City of Richmond and the Greater Richmond Partnership to secure the project for Virginia. Governor Northam approved a $675,000 grant from the Commonwealth’s Opportunity Fund to assist the City of Richmond with the project.

Support for GSK Consumer Healthcare’s job creation will be provided through the Virginia Talent Accelerator Program, a new workforce initiative created by VEDP in collaboration with the Virginia Community College System, with funding support from the Northam administration and the Virginia General Assembly. Launched in 2019, the program accelerates new facility start-ups through the direct delivery of recruitment and training services that are fully customized to a company’s unique products, processes, equipment, standards, and culture. All program services are provided at no cost to qualified new and expanding companies as an incentive for job creation. GSK Consumer Healthcare represents the second company to benefit from the Virginia Talent Accelerator Program.

  ------   News Item Archive  -----  
The Virginia Engineer on facebook
The Virginia Engineer RSS Feed